Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Briacell Therapeutics Corp (BCTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: BCTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -63.17% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.14M USD | Price to earnings Ratio - | 1Y Target Price 23.5 |
Price to earnings Ratio - | 1Y Target Price 23.5 | ||
Volume (30-day avg) 757843 | Beta 1.72 | 52 Weeks Range 2.81 - 21.45 | Updated Date 06/19/2025 |
52 Weeks Range 2.81 - 21.45 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.69 |
Earnings Date
Report Date 2025-06-12 | When After Market | Estimate -1.76 | Actual -1.64 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -131.54% | Return on Equity (TTM) -688.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8801155 | Price to Sales(TTM) - |
Enterprise Value 8801155 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.38 | Shares Outstanding 6776110 | Shares Floating 5668743 |
Shares Outstanding 6776110 | Shares Floating 5668743 | ||
Percent Insiders 7.33 | Percent Institutions 10.88 |
Analyst Ratings
Rating 4.5 | Target Price 23.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Briacell Therapeutics Corp
Company Overview
History and Background
Briacell Therapeutics Corp is a clinical-stage immunotherapy company focused on developing immunotherapies to fight cancer. Founded with the goal of enhancing the body's natural mechanisms to fight cancer, the company has progressed through preclinical and clinical trials with its lead product candidates.
Core Business Areas
- Oncology Immunotherapy: Focuses on developing cancer immunotherapies, primarily using its BriaVaxu2122 and Bria-IMTu2122 platforms. These therapies aim to activate the patient's immune system to recognize and destroy cancer cells.
Leadership and Structure
The company's leadership team consists of experienced professionals in biotechnology, oncology, and clinical development. The organizational structure supports research and development, clinical trials, and business development activities.
Top Products and Market Share
Key Offerings
- BriaVaxu2122: BriaVaxu2122 is Briacell's lead candidate, an off-the-shelf personalized immunotherapy. It's designed to activate T cells to target and destroy cancer cells, primarily in advanced breast cancer. As a clinical-stage therapy, it doesn't currently have market share or generate revenue. Competitors include companies developing other immunotherapies for breast cancer, such as Merck (Keytruda) and Roche (Tecentriq).
- Bria-IMTu2122: Bria-IMTu2122 (Bria Immunotherapy Master Treatment) is a personalized immunotherapy approach that combines BriaVaxu2122 with other immunomodulatory agents. As a clinical-stage therapy, it doesn't currently have market share or generate revenue. Competitors include companies developing personalized cancer treatments, such as BioNTech and Moderna.
Market Dynamics
Industry Overview
The oncology immunotherapy market is experiencing substantial growth, driven by advancements in understanding the immune system and the development of novel therapies that harness the body's natural defenses to fight cancer. The market is competitive, with numerous companies developing immunotherapies for various cancer types.
Positioning
Briacell is positioned as a clinical-stage company focused on personalized immunotherapy. Its BriaVaxu2122 and Bria-IMTu2122 platforms offer a unique approach to cancer treatment, potentially providing a more targeted and effective therapy compared to traditional treatments. Its competitive advantage lies in its personalized approach.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of USD. Briacell is positioned to capture a portion of this TAM with its personalized immunotherapy approaches, particularly in advanced breast cancer.
Upturn SWOT Analysis
Strengths
- Personalized immunotherapy approach
- Proprietary BriaVaxu2122 and Bria-IMTu2122 platforms
- Clinical-stage product candidates
- Experienced leadership team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Competition from larger pharmaceutical companies
- No currently marketed products
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in immunotherapy technology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Economic downturn
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
Briacell faces intense competition from larger pharmaceutical companies with established immunotherapy products. Its personalized approach offers a potential advantage, but it must demonstrate superior efficacy and safety in clinical trials.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the advancement of its clinical programs and expansion of its intellectual property portfolio. Revenue generation is expected upon successful commercialization of BriaVaxu2122 or Bria-IMTu2122.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely, reflecting the uncertainty inherent in biotechnology development.
Recent Initiatives: Recent initiatives include advancing clinical trials for BriaVaxu2122 and Bria-IMTu2122, presenting data at scientific conferences, and seeking strategic partnerships.
Summary
Briacell Therapeutics is a clinical-stage immunotherapy company with a focus on personalized cancer treatments. Its BriaVaxu2122 and Bria-IMTu2122 platforms offer a novel approach, but the company faces significant financial constraints and fierce competition from larger pharmaceutical players. Success hinges on positive clinical trial outcomes and securing strategic partnerships. Investors should monitor clinical trial progress and financial stability closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and thorough due diligence. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Briacell Therapeutics Corp
Exchange NASDAQ | Headquaters West Vancouver, BC, Canada | ||
IPO Launch date 2021-02-24 | CEO, President & Director Dr. William V. Williams FCPA, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://briacell.com |
Full time employees - | Website https://briacell.com | ||
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.